Abstract
One of the more worrying trends in globalization today is the growing practice of western companies relocating clinical trials to impoverished countries. This paper starts by providing a comprehensive description of the practice and its current regulatory oversight. It argues that this regulatory scheme is insufficient in protecting the interests of test subjects in such relocated trials. It then suggests an alternative scheme, embedded in the general framework of human rights protections, and develops the contours of such a human rights-based regulatory scheme. It concludes by arguing why this alternative regulative framework does a better job of protecting the interests of test subjects than those regulatory schemes currently available: the Declaration of Helsinki and the statement of Good Clinical Practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
